Hyloris Pharmaceuticals (LTS:0AB6) PE Ratio without NRI: At Loss (As of Jul. 05, 2026)


LTS:0AB6 Hyloris Pharmaceuticals SA LTS:0AB6
64 GF Score
Price €4.49
GF Value €9.47
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Hyloris Pharmaceuticals PE Ratio without NRI?

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2026-07-05), Hyloris Pharmaceuticals's share price is €4.49. Hyloris Pharmaceuticals's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.27. Therefore, Hyloris Pharmaceuticals's PE Ratio without NRI for today is At Loss.

Hyloris Pharmaceuticals's EPS without NRI for the six months ended in Dec. 2025 was €-0.14. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.27.

As of today (2026-07-05), Hyloris Pharmaceuticals's share price is €4.49. Hyloris Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.23. Therefore, Hyloris Pharmaceuticals's PE Ratio (TTM) for today is At Loss.

Hyloris Pharmaceuticals's EPS (Diluted) for the six months ended in Dec. 2025 was €-0.10. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.23.

Hyloris Pharmaceuticals's EPS (Basic) for the six months ended in Dec. 2025 was €-0.10. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.23.


Hyloris Pharmaceuticals  (LTS:0AB6) PE Ratio without NRI Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio without NRI measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.


Hyloris Pharmaceuticals PE Ratio without NRI Related Terms


Hyloris Pharmaceuticals PE Ratio without NRI Historical Data

* Premium members only.

The historical data trend for Hyloris Pharmaceuticals's PE Ratio without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hyloris Pharmaceuticals PE Ratio without NRI Chart

Hyloris Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PE Ratio without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only N/A At Loss At Loss At Loss At Loss

Hyloris Pharmaceuticals Semi-Annual Data
Dec16 Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
PE Ratio without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

LTS:0AB6 vs VRTX, REGN, ALNY: PE Ratio without NRI Comparison

For the Biotechnology subindustry, Hyloris Pharmaceuticals's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hyloris Pharmaceuticals PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hyloris Pharmaceuticals's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Hyloris Pharmaceuticals's PE Ratio without NRI falls into.


LTS:0AB6
64GF Score
Hyloris Pharmaceuticals SA LTS:0AB6
PE Ratio without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hyloris Pharmaceuticals PE Ratio without NRI Calculation

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.

Hyloris Pharmaceuticals's PE Ratio without NRI for today is calculated as

PE Ratio without NRI=Share Price/ EPS without NRI
=4.49/-0.270
=-16.63(At Loss)

Hyloris Pharmaceuticals's Share Price of today is €4.49.
For company reported semi-annually, Hyloris Pharmaceuticals's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.27.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.

For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Is Hyloris Pharmaceuticals (LTS:0AB6) Overvalued in 2026?

Based on GuruFocus' analysis, Hyloris Pharmaceuticals stock appears to be undervalued. The current stock price of €4.49 is trading 52.6% below its estimated GF Value™ of €9.47. GuruFocus considers Hyloris Pharmaceuticals to be Possible Value Trap.

Key valuation signals for LTS:0AB6:

  • PE Ratio without NRI: At Loss
  • GF Value™: €9.47 vs. price of €4.49 (52.6% below fair value)
  • GF Score™: 64/100 with 3 warning signs

No single metric tells the full story. See the LTS:0AB6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Hyloris Pharmaceuticals Business Description

Other Exchanges 52U:GermanyHYL:Belgium
Address Boulevard Patience et Beaujonc No. 3/1, Liege, BEL, 4000
Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans areas such as cardiovascular, other reformulations, and established markets (high-barrier generics). It has three early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, Podofilox Ge, and Maxigesic IV. Its revenue is mainly generated in the United States.
64GF Score

Get the complete analysis for LTS:0AB6

PE Ratio without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.49
Price
€9.47
GF Value